Stocky turns companies like XVIVO PERFUSION AB UNSP ADR EAC into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. XVIPY scores 52/100 on Growth Compounder metrics but faces a Vulnerability Index of 100—limited financial buffer against downturns. Leadership Alignment (45/100) lags, suggesting misalignment between insider incentives and shareholder interests. While growth signals exist, thin cash reserves and weak governance offset near-term upside.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for XVIVO PERFUSION AB UNSP ADR EAC:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 55/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates XVIVO PERFUSION AB UNSP ADR EAC (XVIPY) at 55/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. XVIPY scores 52/100 on Growth Compounder metrics but faces a Vulnerability Index of 100—limited financial buffer against downturns. Leadership Alignment (45/100) lags, suggesting misalignment between insider incentives and shareho
XVIPY's current Stocky Verdict is 55/100, placing it in the "Cautious" band. This composite combines a 52/100 Compounder score, 45/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for XVIVO PERFUSION AB UNSP ADR EAC yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
XVIVO PERFUSION AB UNSP ADR EAC scores 45/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
XVIVO PERFUSION AB UNSP ADR EAC's Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to XVIVO PERFUSION AB UNSP ADR EAC.
Sign up free and unlock the full analysis on XVIPY — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for XVIPY in the app.
